CureDuchenne Partners with Baebies to Improve Early Detection of DMD

A health care executive with over two decades of leadership experience, Jeffrey Goffman serves as the chairman and CEO of Integrated Oncology Network, LLC. Alongside his activities at the California-based company, Jeffrey Goffman leads the board of directors of CureDuchenne, a nonprofit that works to advance new treatments for Duchenne muscular dystrophy (DMD).

In a recently released statement, CureDuchenne announced that it is partnering with Baebies to help improve early identification of DMD, which primarily affects young boys. As part of the three-year partnership with CureDuchenne, Baebies is expanding its newborn screening service to include the lethal form of muscular dystrophy.

This new screening option funded by CureDuchenne will give parents the ability to identify newborns affected with DMD within the first few weeks of birth. With early detection, treatment can begin as quickly as possible, and researchers will have the opportunity to gain a better understanding of DMD symptoms at the onset.

Including the latest partnership with Baebies, CureDuchenne has now directed over $1.3 billion toward DMD research and treatment. To stay up to date on the organization’s latest work, visit www.cureduchenne.org.